Axcynsis Therapeutics Company Profile

Background

Axcynsis Therapeutics, formerly known as Tetris Therapeutics, is a Singapore-based biotechnology company established in 2022. The company specializes in the development of Antibody-Drug Conjugates (ADCs) aimed at revolutionizing cancer treatment. Axcynsis is committed to advancing effective and targeted oncology therapeutics with breakthrough potential to improve the lives of cancer patients worldwide.

Key Strategic Focus

Axcynsis Therapeutics focuses on developing a robust pipeline of ADC candidates to address unmet medical needs in oncology. The company's core objectives include:

Development of Antibody-Drug Conjugates (ADCs): Leveraging proprietary technologies to create next-generation ADCs with enhanced efficacy and safety profiles.

Proprietary Technologies: Utilizing platforms such as AxcynMAB™ for antibody discovery, AxcynCYS™ for site-specific conjugation, and AxcynDOT™ for novel payloads.

Targeted Therapeutics: Focusing on cancers overexpressing specific antigens like CLDN6, prevalent in lung, ovarian, endometrial, uterine, testicular, and gastric cancers.

Financials and Funding

In May 2022, Axcynsis Therapeutics raised $15 million in seed funding, marking one of the largest seed funds raised by a Singapore-based biotechnology company. The company is currently in progress with a Series A funding round initiated in August 2024. Notable investors include Hapi Investment Management and Trinity Innovation Bioventure Singapore. The capital is intended to support the advancement of the company's ADC pipeline and the initiation of clinical trials.

Pipeline Development

Axcynsis's lead candidate, AT03-65, is a differentiated ADC targeting CLDN6-positive solid tumors. The U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application in January 2025. A Phase 1 multicenter clinical trial in the United States is planned for the first quarter of 2025 to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AT03-65 in patients with advanced CLDN6-positive solid tumors.

Technological Platform and Innovation

Axcynsis Therapeutics distinguishes itself through several proprietary technologies:

AxcynMAB™: A platform for antibody discovery, enabling the development of high-affinity and specific monoclonal antibodies.

AxcynCYS™: A site-specific conjugation technology ensuring consistent and stable attachment of payloads to antibodies.

AxcynDOT™: A proprietary payload derived from trabectedin, an approved chemotherapy agent, optimized for enhanced potency and improved safety profile.

These platforms collectively contribute to the development of next-generation ADCs with potential first-in-class and best-in-class profiles.

Leadership Team

Dr. Zou Bin, Ph.D. – Founder, Chief Executive Officer, and Chairman. Dr. Zou has been instrumental in steering Axcynsis's strategic direction and technological advancements.

Yun Xuan Wong – Operations Manager. Ms. Wong oversees the company's operational activities, ensuring alignment with strategic goals.

The company has also strengthened its scientific advisory board with notable appointments:

Professor Patricia LoRusso, D.O. – A globally recognized expert in early-phase clinical trials and drug development, joined the board in December 2024.

Professor Kyriacos Costa Nicolaou – Renowned for his contributions to chemistry and drug discovery, appointed in May 2023.

Emeritus Professor Paul Herrling – An esteemed figure in pharmaceutical research, joined the board in April 2023.

Competitor Profile

Market Insights and Dynamics

The global ADC market is experiencing significant growth, driven by the increasing prevalence of cancer and the demand for targeted therapies. Advancements in ADC technology, including improved linker and payload designs, are enhancing therapeutic efficacy and safety profiles.

Competitor Analysis

Axcynsis Therapeutics operates in a competitive landscape with several notable companies:

Tmunity Therapeutics: Focuses on next-generation T cell immunotherapies for various diseases.

Harbour BioMed: Specializes in immuno-oncology therapeutics, developing innovative treatments for cancer.

Celularity: Develops allogeneic cell therapies derived from postpartum placenta for cancer treatment.

Quentis Therapeutics: Develops immunotherapies targeting the endoplasmic reticulum stress response to enhance the immune system's ability to fight cancer.

These competitors are also advancing in the field of targeted cancer therapies, contributing to a dynamic and rapidly evolving market.

Strategic Collaborations and Partnerships

Axcynsis Therapeutics has engaged in strategic collaborations to bolster its market position and innovation capacity. Notably, the company participated in the WuXi AppTec BOLD program in July 2023, joining other international biotech entrepreneurs to address unmet needs in oncology.

Operational Insights

Axcynsis's proprietary technologies, including AxcynMAB™, AxcynCYS™, and AxcynDOT™, provide distinct competitive advantages by enabling the development of highly specific and potent ADCs. The company's focus on targeting CLDN6-positive tumors addresses a significant unmet medical need, positioning it favorably in the oncology therapeutics market.

Strategic Opportunities and Future Directions

Axcynsis Therapeutics is poised to expand its pipeline of ADC candidates, leveraging its proprietary platforms to develop therapies for various cancer types. The successful initiation and progression of clinical trials for AT03-65 will be pivotal in establishing the company's credibility and market presence. Continued strategic partnerships and potential collaborations with larger pharmaceutical companies could further accelerate development and commercialization efforts.